| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Rein Therapeutics Inc Com (New) | LTI-01 | Loculated pleural effusions (LPEs) | Phase 2b | Trial Planned | Intravenous | Respiratory |
| Rein Therapeutics Inc Com (New) | LTI-03 - (Caveolin-1) | Idiopathic pulmonary fibrosis (IPF) | Phase 2 | Trial Planned | Inhalation | Respiratory |
| Relay Therapeutics Inc. | Zovegalisib (RLY-2608) + fulvestrant + ribociclib triplet combination - (ReDiscover-2) | PIK3CA (PI3Kα) mutant tumors, including HR+/HER2- breast cancer | Phase 3 | Ongoing | Oral | Oncology |
| Relmada Therapeutics Inc. | REL-1017 - (RELIANCE III) | Major Depressive Disorder (MDD) | Phase 3 | Trial Completed | oral | Psychiatric |
| Relmada Therapeutics Inc. | REL-1017 - (RELIANCE II) | Major depressive disorder (MDD) | Phase 3 | Trial Discontinued | Oral | Psychiatric |
| Relmada Therapeutics Inc. | REL-1017 - (RELIANCE I) | Major depressive disorder (MDD) | Phase 3 | Trial Completed | oral | Psychiatric |
| Relmada Therapeutics Inc. | REL-1017 - (Relight) | Major Depressive Disorder (MDD) | Phase 3 | Trial Discontinued | Oral | Psychiatric |
| Relmada Therapeutics Inc. | REL-1017 - (Reliance-OLS study 310) | Major Depressive Disorder (MDD) | Phase 3 | Trial Completed | oral | Psychiatric |